My personal PT is more like $7-$8. Buyout PT is about $15-$20. But the point is the UPGRADE by Zacks - they tend to be conservative and somewhat "old school " in their evaluations, EPS etc. This stock is going a whole lot higher than $6.25-Zacks PT.
...use a SELL STOP. The MM see's your sell point and can now judge how far to drop the stock to take your shares and clear a bunch of Sell Stop from you rookies...you lock in your losses...so now the MM turning around and selling your shares higher. Don't play their game. if you must, have a "mental Sell Stop ". You are giving the MM the advantage using a Sell Stop.
Geez, I am tired of all your cry baby posts regarding the CEO. Again, if he is so bad why don't you sell your 200 shares and move on. The CEO is not going anywhere, not buying shares to please you and not hiding from the boggy man. So last chance, one more and I will be done with you. I will send you into the abyss.... IGNORELAND.
mf'er, you have totally blown it. You had the opportunity to buy ACAD when it was $30+ and what did you do - bet it would drop lower with a H&S pattern,.If I recall you said it would drop to $15. Later you said $20 then $25... I laughed at you then and I am laughing at you again. Shorts have no play here. They have all lost big time. Flip to a long position and get at least some of your money back. Its not too late. Start with a small position, if it goes up your in the money- if it goes down add to your holdings. Your position at this point can't make you any money anyway, for its over in Sept( so you say)and ACAD has till the end of the year to do the NDA. Even if its delayed again YOU STILL LOST. So no matter what you do you already lost all your short investment. Get your money back.
Gee, you make it sold like the 25Mil shares are sold retail, 100 here, 500 there. It doesn't work that way. Who needs these shares? The hedge funds that shorted 50 million shares- thats who and they will buy a ton at one time via Cowen et al. They are not sitting there buying 100 shares. The offer will probably be over subscribed anyway. Holding your short over the weekend is a huge risk. When shorts start screaming non-sense they are close to walking into the light. Have a nice weekend.
Worst management, weak product with good technology, worst promotion of a product in mankind(pun), weak stats, no shareholder value. And who's fault is it. Something needs to change.
I doubt very much IR would ever give any info what so ever that isn't already news. If she ( Lisa B.) did , she would be fired. Her job title does not allow her to give "her opinion " or forcasts. Only IR issues, eg, stock info, direct you to the various pages on the web site etc. Everyone who has ever spoke with IR ( Lisa B) knows that. When you make #$%$ up you don't help the stock.
NUPLAZID/Pimavanserin is ONE OF A KIND, FIRST IN ITS CLASS drug to treat Parkinson's Disease Psychosis (PDP). And ACAD owns the World Wide Rights to it. The FDA has already reviewed the Phase3 research data and given ACAD thumbs up to proceed with the New Drug Application and has given Pima " Breakthrough Therapy Designation " USA sales will be over 1.1 BILLION and European Union will be well over a Billion as well. There are several other ongoing studies.. The manufacturing arm of the NDA is getting the close attention it should of had last year- it will take some time for new directors & CMO 's to get the systems ready & on line for the FDA evaluations. ..Review the catalyst list-
1) New CEO who can led us to Drug Approval and move the company forward.
2) Possible Partnership with a MAJOR drug company that will assure the NDA will meet and exceed all the FDA standards.
3) NDA on track to be submitted in the 2nd half of 2015. NDA is complete, manufacturing quality systems on track.
3) 60 days for the FDA (Food and Drug Administration ) to accept the application by about Q1 2016.
4) Upon potential acceptance, FDA could also grant priority review.
5) With priority review, six months pdufa date (Prescription Drug User Fee Act ), without, 10 months. Best guess is July to Oct 2016.
6) EU ( European Union ) filing 6- 9 months post FDA filing. Perhaps Q2-3 2016. Large unmet need in EU.
7) ADP enrollment (019 study) complete by 2015 Q4 and data by about Q2 2016
8) Schizophrenia maintenance trial to commence 2nd half of 2015.
9) Sleep Study to begin 2nd half of 2015.
There are NO ongoing issues with the FDA.
When you are CEO of a small company that is bound for a huge uptake in MK, 1mil shares is a nice bonus and well deserved. Now COVER your bung shorty.
Its a "no brainier" for any Biotech to buy ACAD. Biogen would be out bid by MRK anyway.
My message board is clean. If you allow the dimwits to stay on your view then its your choice. AND THE IDIOTS WILL THANK YOU BY PUTTING UP MORE GARBAGE EACH AND EVERY TIME YOU REPLY TO THEM OR ABOUT THEM. I don't play their stupid game. I just place ALL the IDIOTS and MORONS on IGNORE and move on. I don't even think twice about it. This board, in my view, is CLEAN, and I share whatever info I have with my fellow longs with no regard to idiots.
"Cabo RCC= 300M" is low. Afinitor cost over $11+K per month. And can be used well over a yr. So rev's could be over 400-500Mill once the penetration rate increases.
Btw...to ALL MORON SHORTS out there. See the way it works is I place you on Iggy and toss your fat A.$.$ into general population. Where all kinds of shenanigans go on by the other little mischief makers & pranksters. Did you see The Shawshank Redemption ...like that. So I bet you foregot the peanut butter didn't you. You have to be prepared. Oh, I can not see your post, nor do I care to. I don't play your game. You play mine. You get your panties in a knock and bark at me, and do me the wonderful favor of bumping my Ignore list back to the TOP. I thank you. Have an enjoyable night (OUCH!)....FRESH FISH, FRESH FISH, FRESH FISH....
There are also 2 SEC Filings reg the Proxy material and voting, Shareholder meeting etc..
What am I voting on?
There are five matters scheduled for a vote:
• Election of three Class II directors, Stephen R. Biggar, M.D., Ph.D., Torsten Rasmussen and Daniel Soland, to hold office until our 2018 Annual Meeting of Stockholders;
• Approval of an amendment to the Company’s 2010 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.
• Approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 225,000,000.
• Advisory approval of the compensation of the Company’s named executive officers, as disclosed in this proxy statement in accordance with SEC rules; and
• Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
stanley_rnyron_kederski, tagetlocman , portsrnouthohio (on double secret probation) , rii_666, elmaestro111, kathycronkite ,crecy_wart_knight, cathycronkite, mercury7astro, harvardphd1972, donnatello465, harvardmba1972, zoom69zoom, bobkidder89 AND of course the WORST OFFENDER IS ri66, supposedly a long who posts the same mindless $h.it all frigin day.